Tan Wan C, Lo Christine, Jong Aimee, Xing Li, Fitzgerald Mark J, Vollmer William M, Buist Sonia A, Sin Don D
iCapture Centre for Cardiovascular and Pulmonary Research, St. Paul's Hospital and the University of British Columbia, Vancouver, Canada.
CMAJ. 2009 Apr 14;180(8):814-20. doi: 10.1503/cmaj.081040.
Our aim was to determine the combined and independent effects of tobacco and marijuana smoking on respiratory symptoms and chronic obstructive pulmonary disease (COPD) in the general population.
We surveyed a random sample of 878 people aged 40 years or older living in Vancouver, Canada, about their respiratory history and their history of tobacco and marijuana smoking. We performed spirometric testing before and after administration of 200 microg of salbutamol. We examined the association between tobacco and marijuana smoking and COPD.
The prevalence of a history of smoking in this sample was 45.5% (95% confidence interval [CI] 42.2%-48.8%) for marijuana use and 53.1% (95% CI 49.8%-56.4%) for tobacco use. The prevalence of current smoking (in the past 12 months) was 14% for marijuana use and 14% for tobacco use. Compared with nonsmokers, participants who reported smoking only tobacco, but not those who reported smoking only marijuana, experienced more frequent respiratory symptoms (odds ratio [OR] 1.50, 95% CI 1.05-2.14) and were more likely to have COPD (OR 2.74, 95% CI 1.66-4.52). Concurrent use of marijuana and tobacco was associated with increased risk (adjusted for age, asthma and comorbidities) of respiratory symptoms (OR 2.39, 95% CI 1.58-3.62) and COPD (OR 2.90, 95% CI 1.53-5.51) if the lifetime dose of marijuana exceeded 50 marijuana cigarettes. The risks of respiratory symptoms and of COPD were related to a synergistic interaction between marijuana and tobacco.
Smoking both tobacco and marijuana synergistically increased the risk of respiratory symptoms and COPD. Smoking only marijuana was not associated with an increased risk of respiratory symptoms or COPD.
我们的目的是确定吸烟与吸食大麻对普通人群呼吸道症状和慢性阻塞性肺疾病(COPD)的综合及独立影响。
我们对加拿大温哥华878名40岁及以上的人群进行了随机抽样调查,询问他们的呼吸病史以及吸烟和吸食大麻史。在给予200微克沙丁胺醇前后进行了肺功能测试。我们研究了吸烟和吸食大麻与慢性阻塞性肺疾病之间的关联。
该样本中吸食大麻的吸烟史患病率为45.5%(95%置信区间[CI]42.2%-48.8%),吸烟的患病率为53.1%(95%CI 49.8%-56.4%)。当前吸烟(过去12个月内)的大麻使用率为14%,烟草使用率为14%。与不吸烟者相比,仅报告吸烟但不包括仅报告吸食大麻的参与者,出现呼吸道症状的频率更高(优势比[OR]1.50,95%CI 1.05-2.14),且更有可能患有慢性阻塞性肺疾病(OR 2.74,95%CI 1.66-4.52)。如果大麻的终身使用量超过50支大麻卷烟,同时使用大麻和烟草会增加呼吸道症状(校正年龄、哮喘和合并症后,OR 2.39,95%CI 1.58-3.62)和慢性阻塞性肺疾病(OR 2.90,95%CI 1.53-5.51)的风险。呼吸道症状和慢性阻塞性肺疾病的风险与大麻和烟草之间的协同相互作用有关。
同时吸烟和吸食大麻会协同增加呼吸道症状和慢性阻塞性肺疾病的风险。仅吸食大麻与呼吸道症状或慢性阻塞性肺疾病风险增加无关。